<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643327</url>
  </required_header>
  <id_info>
    <org_study_id>HREC/2020/QRBW/69379</org_study_id>
    <nct_id>NCT04643327</nct_id>
  </id_info>
  <brief_title>Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease</brief_title>
  <acronym>TRIP</acronym>
  <official_title>Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queensland University of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cleveland Clinic Lou Ruvo Center for Brain Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brisbane and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a&#xD;
      repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's&#xD;
      disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on&#xD;
      specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD&#xD;
      patients with memory problems will be compared to PD patients without memory problems and&#xD;
      healthy older adults to determine if activity in specific brain regions (hippocampal&#xD;
      subfields) can be used to predict memory problems in PD. This information will be useful for&#xD;
      future clinical trials to target drugs to these brain regions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blind randomised-controlled within-subject crossover trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pattern separation performance (behavioural outcome)</measure>
    <time_frame>Immediately after 2 weeks of treatment</time_frame>
    <description>Participants' behavioural performance on the pattern separation fMRI paradigm, as measured by their proportionate accuracy of identifying the critical &quot;lure&quot; trials.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hippocampal DG/CA3 subfield activity</measure>
    <time_frame>Immediately after 2 weeks of treatment</time_frame>
    <description>Participants' brain activation during the pattern separation fMRI paradigm, as measured by their activation in the critical dentate gyrus (DG)/CA3 subfield of the hippocampus during the critical &quot;lure&quot; trials of the pattern separation task.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Memory Impairment</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125mg Levetiracetam capsules taken twice daily (morning and evening) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>125mg maize starch-based placebo capsules taken twice daily (morning and evening) for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.</description>
    <arm_group_label>Active arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's Disease patients with amnestic Mild Cognitive Impairment&#xD;
&#xD;
          -  Parkinson's Disease patients with no memory impairment&#xD;
&#xD;
          -  Healthy volunteers&#xD;
&#xD;
          -  All participants must be eligible to take MRI scans&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Contraindication to having MRI&#xD;
&#xD;
          -  Bipolar disorder, Schizophrenia, Alcohol or substance abuse&#xD;
&#xD;
          -  Major depression&#xD;
&#xD;
          -  Suicidal Ideation&#xD;
&#xD;
          -  Difficulty complying with protocol requirements&#xD;
&#xD;
          -  Significant non-PD neurological disease&#xD;
&#xD;
          -  Vascular dementia&#xD;
&#xD;
          -  Sensitivity to levetiracetam&#xD;
&#xD;
          -  Use of anticonvulsant medications&#xD;
&#xD;
          -  Use of other excluded medications&#xD;
&#xD;
          -  Severe renal impairment&#xD;
&#xD;
          -  Clinically significant abnormalities in B12 or thyroid function test (below normative&#xD;
             range for elderly)&#xD;
&#xD;
          -  Females of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Queensland Centre for Clinical Research</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Pourzinal, BSc</last_name>
      <phone>0733465028</phone>
      <email>pd.research@uq.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Queensland</investigator_affiliation>
    <investigator_full_name>Nadeeka Dissanyaka</investigator_full_name>
    <investigator_title>NHMRC Boosting Dementia Research Leadership Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

